FDA Approves Pembrolizumab for Frontline PD-L1+ NSCLC

The FDA has approved pembrolizumab (Keytruda) for the frontline treatment of patients with metastatic non­–small cell lung cancer (NSCLC) whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations. The approval is based on data from the phase III KEYNOTE-024 trial, in which single-agent pembrolizumab reduced the risk … (leggi tutto)